---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107299"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:51:59.774098+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M

## Summary
- Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).
- Cash and cash equivalents $264.5M as of June 30, 2025 vs $196.8M at Dec 31, 2024; runway into H2 2027.
- R&D expenses increased to $28.1M in Q2 2025 from $19.5M in Q2 2024 due to clinical trial costs.
- MZE782 Phase 1 proof-of-mechanism data expected Q3 2025; MZE829 Phase 2 HORIZON data expected Q1 2026.
- No license revenue recognized in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-107299
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/0000950170-25-107299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107299
- JSON: https://secwatch.observer/filing/0000950170-25-107299.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.